Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 4, 1999, Pages 380-390

  Shangraw, Robert E ^a,b,c   Fisher, Dennis M ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICHLOROACETIC ACID; GLUCOSE; GLYCOGEN; LACTIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; FEMALE; GLUCONEOGENESIS; GLYCOGEN LIVER LEVEL; HUMAN; HYPOGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LACTATE BLOOD LEVEL; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DICHLOROACETATE; FEMALE; HUMANS; HYPOGLYCEMIA; LACTIC ACID; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0032742775     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.a101340     Document Type: Article

References (36)

1. 1. Phillips JW, Clark DG, Henly DC, Berry MN. The contribution of glucose cycling to the maintenance of steady-state levels of lactate by hepatocytes during glycolysis and gluconeogenesis. Eur J Biochem 1995;227:352-8.
2. 2. Behal RH, Buxton DB, Robertson JG, Olson MS. Regulation of the pyruvate dehydrogenase multienzyme complex. Annu Rev Nutr 1993;13:497-520.
3. 3. Sugden MC, Holness MJ. Interactive regulation of the pyruvate dehydrogenase complex and the carnitine palmitoyltransferase system. FASEB J 1994;8:54-61.
4. 4. Shangraw RE, Rabkin JM, Lopaschuk GD. Hepatic pyruvate dehydrogenase activity in humans: effect of cirrhosis, transplantation, and dichloroacetate. Am J Physiol 1998;274:G569-77.
5. 5. Giardina MG, Matarazzo M, Sacca L. Kinetic analysis of glycogen synthase and PDC in cirrhotic rat liver and skeletal muscle. Am J Physiol 1994;267:E900-6.
6. 6. Fregeau DR, Roche TE, Davis PA, Coppel R, Gershwin ME. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1α, a non-lipoic acid containing mitochondrial enzyme. J Immunol 1990;144:1671-6.
7. 7. Woll PJ, Record CO. Lactate elimination in man: effect of lactate concentration and hepatic dysfunction. Eur J Clin Invest 1979;9:397-404.
8. 8. Shangraw RE, Winter R, Hromco J, Robinson ST, Gallaher EJ. Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans. Anesthesiology 1994;81:1127-38.
9. 9. Wyke RJ. Problems of bacterial infection in patients with liver disease. Gut 1987;28:623-41.
10. 10. Whitehouse S, Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 1974; 141:761-74.
11. 11. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism 1989;38:1124-44.
12. 12. Jahoor F, Peters EJ, Wolfe RR. The relationship between gluconeogenic substrate supply and glucose production in humans. Am J Physiol 1990;258(2 Pt 1):E288-96.
13. 13. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med 1992;327:1564-9.
14. 14. Lukas G, Vyas KH, Brindle SD, LeSher AR, Wagner WE Jr. Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. J Pharm Sci 1980;69:419-21.
15. 15. Demaugre F, Cepanec C, LeRoux JP. Characterization of oxalate as a catabolite of dichloroacetate responsible for the inhibition of gluconeogenesis and pyruvate carboxylation in rat liver cells. Biochem Biophys Res Commun 1978;85:1180-5.
16. 16. Curry SH, Chu PI, Baumgartner TG, Stacpoole PW. Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin Pharmacol Ther 1985;37:89-93.
17. 17. Shangraw RE, Fisher DM. Pharmacokinetics of dichloroacetate in patients undergoing liver transplantation. Anesthesiology 1996;84:851-8.
18. 18. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
19. 19. Georgopolous D, Berezanski D, Anthonisen NR. Effect of dichloroacetate on ventilatory response to sustained hypoxia in normal adults. Respir Physiol 1990;82:115-22.
20. 20. Fox AW, Sullivan BW, Buffini JD, Neichin ML, Nicora R, Hoehler FK, et al. Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. J Pharmacol Exp Ther 1996;279:686-93.
21. 21. Beal SL, Sheiner S. Methodology of population pharmacokinetics. In: Garrett E, Hirtz J, editors. Drug fate and metabolism: methods and techniques. New York: Marcel Dekker; 1985. p. 135-83.
22. 22. Kelley SD, Cauldwell CB, Fisher DM, Lau M, Sharma ML, Weisiger RA. Recovery of hepatic drug extraction after hypothermic preservation. Anesthesiology 1995;82:251-8.
23. 23. Wells PG, Moore GW, Rabin D, Wilkinson GR, Oates JA, Stacpoole PW. Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. Diabetologia 1980;19:109-13.
24. 24. Lipscomb JC, Mahle DA, Brashear WT, Barton HA. Dichloroacetic acid: metabolism in cytosol. Drug Metab Dispos 1995;23:1202-5.
25. 25. Tong Z, Board PG, Anders MW. Glutathione transferase zeta catalyses the oxygenation of the carcinogen dichloroacetic acid to glyoxylic acid. Biochem J 1998;331:371-4.
26. 26. Bianchi G, Bugianesi E, Ronchi M, Fabbri A, Zoli M, Marchesini G, Glutathione kinetics in normal man and in patients with liver cirrhosis. J Hepatol 1997;26:606-13.
27. 27. Gonzalez-Leon A, Schultz IR, Xu G, Bull RJ. Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prior administration in drinking water. Toxicol Appl Pharmacol 1997;146:189-95.
28. 28. James MO, Cornett R, Yan Z, Henderson GN, Stacpoole PW. Glutathione-dependent conversion to glyoxylate, a major pathway of dichloroacetate biotransformation in hepatic cytosol from humans and rats, is reduced in dichloroacetate-treated rats. Drug Metab Dispos 1997;25: 1223-7.
29. 29. Austin EW, Bull RJ. Effect of pretreatment with dichloroacetate or trichloroacetate on the metabolism of bromodichloroacetate. J Toxicol Environ Health 1997; 52:367-83.
30. 30. Keller U, Sonnenberg GE, Burckhardt D, Perruchoud A. Evidence for an augmented glucagon dependence of hepatic glucose production in cirrhosis of the liver. J Clin Endocrinol Metab 1982;54:961-8.
31. 31. Cavallo-Perin P, Cassader M, Bozzo C, Bruno A, Nuccio P, Dall'Omo AM, et al. Mechanism of insulin resistance in human liver cirrhosis: evidence of a combined receptor and post-receptor defect. J Clin Invest 1985;75: 1659-65.
32. 32. Proietto J, Alford FP, Dudley FJ. The mechanism of the carbohydrate intolerance of cirrhosis. J Clin Endocrinol Metab 1980;51:1030-6.
33. 33. Rosa J, Rosa J, Fister V. Effects of somatostatin on glucagon-stimulated glycogenolysis and gluconeogenesis in hepatocytes cultured in vitro. Acta Physiol Scand 1992;146:205-11.
34. 34. Diamond MP, Rollings RC, Erlendson L, Williams PE, Lacy WW, Rabin D, et al. Dichloroacetate: its in vivo metabolic effects on carbohydrate metabolism in the conscious dog. Diabetes 1980;29:702-9.
35. 35. Crabb DW, Mapes JP, Boersma RW, Harris RA. Effect of dichloroacetate on carbohydrate and lipid metabolism of isolated hepatocytes. Arch Biochem Biophys 1976;173: 658-65.
36. 36. Metcalfe HK, Monson JP, Cohen RD, Padgham C. Enhanced carrier-mediated lactate entry into isolated hepatocytes from starved and diabetic rats. J Biol Chem 1988;263:19505-9.